Beta 2-agonists in asthma.

Beta 2-agonists in asthma.

Opis bibliograficzny
Główni autorzy:	Britton, J, Pavord, I, Wong, C, Tattersfields, A
Format:	Journal article
Język:	English
Wydane:	1991

Podobne zapisy

β2-agonists in asthma
od: Britton, J, i wsp.
Wydane: (1991)

Asthma control during and after cessation of regular beta 2-agonist treatment.
od: Wahedna, I, i wsp.
Wydane: (1993)

Use of long-acting beta2 agonists in arginine-16 homozygous patients with asthma.
od: Green, R, i wsp.
Wydane: (2008)

Beta2-Agonists and Asthma in Children
od: Guy Lapierre
Wydane: (1995-01-01)

Beta-Adrenergic Receptors and Mechanisms in Asthma: The New Long-Acting Beta-Agonists
od: Robert G Townley
Wydane: (1996-01-01)

Canadian Thoracic Society Asthma Committee Commentary on Long-Acting Beta-2 Agonist Use for Asthma in Canada
od: M Diane Lougheed, i wsp.
Wydane: (2010-01-01)

Effect of 443c81, an inhaled mu-opioid receptor agonist in asthma.
od: Pavord, I, i wsp.
Wydane: (1994)

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.
od: Wong, C, i wsp.
Wydane: (1990)

Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?
od: Higgins, R, i wsp.
Wydane: (1988)

What Is the Role of Beta-Agonist Bronchodilators in the Day-to-Day Treatment of Chronic Asthma?
od: Pierre Ernst
Wydane: (1995-01-01)

The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study
od: Rishi Jayant Khusial, i wsp.
Wydane: (2024-12-01)

Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
od: Crossingham, I, i wsp.
Wydane: (2020)

Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists
od: Willson, J, i wsp.
Wydane: (2014)

Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.
od: Willson, J, i wsp.
Wydane: (2014)

The Relationship among the Inspiratory Muscle Strength, the Perception of Dyspnea and Inhaled Beta2-Agonists in Patients with Asthma
od: Paltiel Weiner, i wsp.
Wydane: (2002-01-01)

Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma
od: Crossingham, I, i wsp.
Wydane: (2021)

Effect of inhaled prostaglandin E2 on allergen-induced asthma.
od: Pavord, I, i wsp.
Wydane: (1993)

Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
od: Adrian R. O'Hagan, i wsp.
Wydane: (2012-01-01)

The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis
od: Pavord, I, i wsp.
Wydane: (2017)

Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation
od: Kulalert P, i wsp.
Wydane: (2020-08-01)

Beta-2 agonists for the treatment of bronchiolitis
od: Constanza Gómez, i wsp.
Wydane: (2020-09-01)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
od: Lee SY, i wsp.
Wydane: (2016-11-01)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
od: Heinrich Worth, i wsp.
Wydane: (2021-04-01)

Bronchodilator Responsiveness Measured by Spirometry and Impulse Oscillometry in Patients with Asthma After Short Acting Antimuscarinic and/or Beta-2-Agonists Inhalation
od: van der Burg NMD, i wsp.
Wydane: (2024-01-01)

Beta-Adrenergic Agonists
od: Giovanni Barisione, i wsp.
Wydane: (2010-03-01)

Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia
od: Chin, M.C., i wsp.
Wydane: (2017)

Use of beta-2 agonists and risk of hip fracture
od: De Vries, F, i wsp.
Wydane: (2006)

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
od: Leanne Kaye, i wsp.
Wydane: (2022-09-01)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
od: Scichilone N, i wsp.
Wydane: (2014-11-01)

Asthma phenotypes.
od: Pavord, I
Wydane: (2012)

Cough and asthma.
od: Pavord, I
Wydane: (2004)

β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
od: Paakinaho A, i wsp.
Wydane: (2023-06-01)

New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
od: Koshak Emad
Wydane: (2010-01-01)

The role of polymorphic variants of arginase genes (<i>ARG1, ARG2</i>) involved in beta-2-agonist metabolism in the development and course of asthma
od: O. N. Savelieva, i wsp.
Wydane: (2020-07-01)

A severe tremor caused by a beta2 agonist in a patient with asthma‐chronic obstructive pulmonary disease overlap
od: Kota Nakajima, i wsp.
Wydane: (2024-08-01)

Impulse Oscillometry; Therapeutic Impacts of Transdermal Long-Acting Beta-2 Agonist Patch in Elderly Asthma with Inhaled Corticosteroid Alone
od: Hiroshi Tanaka, i wsp.
Wydane: (2012-01-01)

Asthma as a nonlinear complex dynamic system: a novel approach to understand the temporal behaviour of chronic asthma and its response to beta-agonists
od: Urs Frey
Wydane: (2008-06-01)

The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study
od: Liselot N van den Berg, i wsp.
Wydane: (2024-04-01)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
od: Bateman ED, i wsp.
Wydane: (2018-05-01)

Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia
od: Hao-Chien Wang, MD PhD, i wsp.
Wydane: (2023-10-01)